# Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

> **NCT00874315** · PHASE2 · WITHDRAWN · sponsor: **Nationwide Children's Hospital**

## Conditions studied

- Neuroblastoma

## Interventions

- **OTHER:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00874315
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874315, "Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00874315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*